OR502

OR502 (0.1-100000 ng/mL) dose-dependently binds to LILRB2-expressing HEK293T cells, reaching near-maximal receptor occupancy at the highest tested concentrations^[1].
OR502 (0.01-100 μg/mL) completely blocks the interaction of LILRB2-Fc with HLA-G expressed on B-cell lymphoma 721.221 cells at concentrations of 1 μg/mL and higher^[1].
OR502 decreases LPS-induced IL-10 secretion and enhances LPS-induced IFN-γ secretion by human PBMCs, with superior activity relative to benchmark anti-LILRB2 antibodies^[1].
OR502 (0-40 μg/mL; 72 h) dose-dependently relieves M2c macrophage-mediated suppression of CD8⁺ T cell proliferation and enhances IFN-γ and perforin secretion by CD8⁺ T cells, with superior activity relative to benchmark anti-LILRB2 antibodies^[1].
OR502 (0-0.3 μg/mL) dose-dependently enhances IFN-γ secretion by exhausted T cells in the presence of M2c macrophages, and significantly amplifies pembrolizumab-induced IFN-γ production by exhausted T cells when used in combination^[1].
OR502 both prevents the development of immunosuppressive M2-like macrophages (when administered during polarization) and reprograms existing immunosuppressive M2-like macrophages (when administered post polarization), leading to increased CD8⁺ T cell proliferation, IFN-γ secretion, and perforin secretion in coculture assays^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.